Invivyd, Inc. (IVVD)
(Delayed Data from NSDQ)
$1.11 USD
-0.03 (-2.63%)
Updated Sep 17, 2024 03:59 PM ET
After-Market: $1.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$1.11 USD
-0.03 (-2.63%)
Updated Sep 17, 2024 03:59 PM ET
After-Market: $1.11 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth C Momentum B VGM
Zacks News
Invivyd, Inc. (IVVD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Invivyd, Inc. (IVVD) delivered earnings and revenue surprises of -8.11% and 53.85%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Invivyd, Inc. (IVVD) Rating Upgrade to Strong Buy
by Zacks Equity Research
Invivyd, Inc. (IVVD) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Invivyd (IVVD) Surges on Positive Data From COVID-19 Study
by Zacks Equity Research
Invivyd (IVVD) reports positive initial data from the phase III CANOPY study on VYD222 for the prevention of symptomatic COVID-19. Stock shoots up on the news.
Invivyd (IVVD) Stock Rises 18% in 3 Months: Here's Why
by Zacks Equity Research
Invivyd's (IVVD) shares rallied almost 18% over the past three months, owing to promising developments in its monoclonal antibody candidate, VYD222, designed to prevent symptomatic COVID-19 infection.
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.
Catalent (CTLT) to Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
Catalent's (CTLT) Q3 results are likely to have been driven by robust segmental performances.
Revvity (PKI) to Report Q1 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Revvity's (PKI) first-quarter results are likely to reflect weak performance at the Diagnostics segment, partially offset by strong demand for Life Sciences and Diagnostics franchise.
After Plunging -26.71% in 4 Weeks, Here's Why the Trend Might Reverse for Invivyd, Inc. (IVVD)
by Zacks Equity Research
Invivyd, Inc. (IVVD) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
Invivyd, Inc. (IVVD) Upgraded to Buy: Here's Why
by Zacks Equity Research
Invivyd, Inc. (IVVD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.